Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H27ClF2O5 |
| Molecular Weight | 444.897 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C(Cl)=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
InChI
InChIKey=GGXMRPUKBWXVHE-MIHLVHIWSA-N
InChI=1S/C22H27ClF2O5/c1-10-4-11-12-5-15(24)13-6-16(27)14(23)7-19(13,2)21(12,25)17(28)8-20(11,3)22(10,30)18(29)9-26/h6-7,10-12,15,17,26,28,30H,4-5,8-9H2,1-3H3/t10-,11+,12+,15+,17+,19+,20+,21+,22+/m1/s1
Halometasone, a high-potency topical glucocorticoid that inhibits inflammation, epidermal hyperplasia, and allergic reactions, constrict blood vessels and relieve pruritus. Halometasone as the cream is used for the treatment of patients with chronic psoriasis vulgaris, eczematous dermatoses, and occupational contact dermatitis. Besides, this drug can reduce acute adverse effects induced by pulsed dye laser for the treatment of port wine stain (PWS) birthmarks. Halometasone acts via the binding to steroid receptors to modulate the protein synthesis and to regulate the function of inflammatory cells and lysosomes and ultimately to reduce inflammatory responses.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P04150 Gene ID: 2908.0 Gene Symbol: NR3C1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/29250537 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29250537
1.41% of halometasone cream used for consecutive 7 days on a lesion area of 400 cm2 can be absorbed via the skin
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D07AC12
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
||
|
WHO-VATC |
QD07AC12
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
26416
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | RxNorm | ||
|
4647
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
DB13728
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
9846332
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
1352
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
C036518
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL1587228
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
C170038
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
DTXSID1048382
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
50629-82-8
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
256-664-9
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
100000083923
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
SUB08001MIG
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
m5903
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | Merck Index | ||
|
J69Z9UU41Z
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY | |||
|
HALOMETASONE
Created by
admin on Mon Mar 31 17:35:43 GMT 2025 , Edited by admin on Mon Mar 31 17:35:43 GMT 2025
|
PRIMARY |
ACTIVE MOIETY